BackAvecho Biotechnology Limited Overview

Avecho Biotechnology Limited Profit Margin

Valuation check: AVEFF's profit margin is -343.94%, below the Healthcare sector average of 17.63%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-3227.48%
↓ 575.50% YoY

As of Jun 2026

Annual Profit Margin (TTM)

-343.94%
↑ 44.57% YoY

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Avecho Biotechnology Limited (AVEFF) FAQ

The latest profit margin for AVEFF is -343.94% as of June 2026. That compares with -620.53% in the prior-year period — up 44.6% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Avecho Biotechnology Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, AVEFF's profit margin moved from -620.53% to -343.94% — a 44.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Avecho Biotechnology Limited's valuation or profitability profile.

Against Healthcare companies, AVEFF currently prints -343.94% for profit margin, while the sector average sits near 17.63%. That is roughly 2051.0% below the sector mean. Large gaps often invite a closer look at Avecho Biotechnology Limited's growth, margins, and balance sheet.

Profit Margin shows how effectively Avecho Biotechnology Limited converts resources into returns. At -343.94%, AVEFF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -620.53% in the prior-year period — up 44.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AVEFF's profit margin (-343.94%), review year-over-year change from -620.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.